Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer

INTRODUCTION: The PD-L1 immune checkpoint inhibitors atezolizumab and durvalumab have received regulatory approval for the first-line treatment of patients with extensive-stage small cell lung cancer. However, when used in combination with platinum-based chemotherapy, these PD-L1 inhibitors only imp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Oncol
Egile Nagusiak: Thomas, Portia L., Groves, Sarah M., Zhang, Yun-Kai, Li, Jia, Gonzalez-Ericsson, Paula, Sivagnanam, Shamilene, Betts, Courtney B., Chen, Hua-Chang, Liu, Qi, Lowe, Cindy, Chen, Heidi, Boyd, Kelli L., Kopparapu, Prasad R., Yan, Yingjun, Coussens, Lisa M., Quaranta, Vito, Tyson, Darren R., Iams, Wade, Lovly, Christine M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8222171/
https://ncbi.nlm.nih.gov/pubmed/33839362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2021.03.011
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak